Tectonic Therapeutic (TECX) AI Stock Analysis

• Market Cap: $564.43M
• Dividend Yield: N/A
• Average Volume (3M): 295.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: N/A
• EPS Growth: 60.40%
• Country: US
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 18,776,627
• 10 Day Avg. Volume: 167,677
• 30 Day Avg. Volume: 295,472
• PEG Ratio: -1.69
• Price to Book (P/B): 1.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.34
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -4.36
• 1Y Price Target: $86.50
• Price Target Upside: 187.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -4.85
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $31.00 ▲(3.13% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is anchored by mixed fundamentals: strong capitalization and very low debt are offset by a pre-revenue profile with widening losses and heavy cash burn. Technicals are strong with the stock trading well above moving averages, but overbought indicators raise near-term volatility risk. Valuation is constrained by ongoing losses (negative P/E) and no dividend support.

Positive Factors

Low leverage and stronger capitalization

Very low debt and a marked increase in equity/assets provide durable financial flexibility to fund multi-year GPCR R&D. That balance sheet strength reduces short-term default risk, preserves strategic optionality for partnerships or licensing, and limits immediate pressure to refinance.

Negative Factors

Pre-revenue with widening net losses

Operating without revenue and with accelerating losses is a durable constraint: it forces continued reliance on financing to sustain R&D, raises dilution risk for shareholders, and means the company must achieve clinical progress or deals to materially alter its financial trajectory within months.

Tectonic Therapeutic Business Overview & Revenue Model

Company Description

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform ...

Read more

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform ...

How the Company Makes Money

null...

Tectonic Therapeutic Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-71.48M	-56.23M	-41.19M	-31.03M	-8.12M
Net Income	-74.15M	-57.98M	-42.82M	-32.18M	-8.93M
Balance Sheet
Total Assets	261.04M	152.91M	39.40M	47.21M	32.88M
Cash, Cash Equivalents and Short-Term Investments	253.80M	141.24M	28.77M	35.97M	28.06M
Total Debt	1.28M	3.30M	4.34M	5.79M	1.05M
Total Liabilities	9.71M	12.13M	124.03M	92.86M	47.84M
Stockholders Equity	251.33M	140.78M	-84.64M	-45.65M	-14.96M
Cash Flow
Free Cash Flow	-60.29M	-59.24M	-40.96M	-97.47M	-14.58M
Operating Cash Flow	-60.08M	-59.08M	-40.68M	-97.21M	-12.45M
Investing Cash Flow	-138.00K	-156.00K	-279.00K	-267.00K	-2.12M
Financing Cash Flow	173.35M	171.71M	33.75M	262.00K	41.42M

Tectonic Therapeutic Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 30.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECX, the sentiment is Positive. The current price of 30.06 is below the 20-day moving average (MA) of 30.99, above the 50-day MA of 26.66, and above the 200-day MA of 21.40, indicating a neutral trend. The MACD of 0.74 indicates Positive momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 34.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECX.

Tectonic Therapeutic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TECX	54 Neutral	$564.43M	-5.15	-26.87%	―	―	60.40%
OMER	53 Neutral	$828.68M	―	1.71%	―	―	12.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABEO	49 Neutral	$277.83M	3.92	53.18%	―	―	―
LXEO	49 Neutral	$477.12M	-53.29	-67.33%	―	―	4.97%
FHTX	45 Neutral	$287.04M	-4.58	105.48%	―	-3.91%	37.89%
MREO	42 Neutral	$50.79M	-1.59	-83.02%	―	―	―

Tectonic Therapeutic Corporate Events